Each person is unique. Each cancer is unique. Each medicine must be unique.
We are building an AI-based process that turns genetic and other molecular information about a cancer into custom-made medicines. We’re starting with engineered viruses for dog cancers.
We have already prototyped this process. We made our first medicine, targeting canine osteosarcoma, in 2016. In late 2017 we received a $500,000 seed grant from Deloitte Life Sciences and Health Care to extend this work. Our goal is to scale our production 10X year over year.
To speak with us, learn more about our work, or to enquire about career opportunities, please email: [email protected]